Immunovant Inc. is a clinical-stage immunology company committed to improving the lives of individuals with autoimmune diseases. The company specializes in developing targeted therapies centered around its innovative anti-FcRn technology, which aims to address the complex and diverse needs of patients suffering from these conditions. By focusing on breakthrough treatments, Immunovant aspires to enable normal lives for those affected by autoimmune disorders. The company operates in a dynamic and entrepreneurial environment, emphasizing collaboration and cross-functional teamwork. Immunovant values dedication, innovation, and a results-driven approach, fostering a culture where employees are encouraged to think creatively and challenge the status quo.